Boston Scientific price target raised to $73 from $70 at Truist

Truist raised the firm’s price target on Boston Scientific to $73 from $70 and keeps a Buy rating on the shares after its Q4 earnings beat. The U.S. TAVR timeline delay was a minor disappointment and likely stripped away some stock follow-through to an otherwise excellent quarter, but Farapulse alone should have enough revenue and profit growth momentum to drive meaningful upside, the analyst tells investors in a research note.